AAAAAA
Results: 26-38/38
Authors:
Teerlink, JR
Jalaluddin, M
Anderson, S
Kukin, ML
Eichhorn, EJ
Francis, G
Packer, M
Massie, BM
Citation: Jr. Teerlink et al., Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death, CIRCULATION, 101(1), 2000, pp. 40-46
Current perspectives on the design of phase II trials of new drugs for thetreatment of heart failure
Authors:
Packer, M
Citation: M. Packer, Current perspectives on the design of phase II trials of new drugs for thetreatment of heart failure, AM HEART J, 139(4), 2000, pp. S202-S206
Authors:
Moe, GW
Rouleau, JL
Charbonneau, L
Proulx, G
Arnold, JMO
Hall, C
de Champlain, J
Barr, A
Sirois, P
Packer, M
Citation: Gw. Moe et al., Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan, AM HEART J, 139(4), 2000, pp. 587-595
Authors:
Udelson, JE
DeAbate, CA
Berk, M
Neuberg, G
Packer, M
Vijay, NK
Gorwitt, J
Smith, WB
Kukin, ML
LeJemtel, T
Levine, TB
Konstam, MA
Citation: Je. Udelson et al., Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction, AM HEART J, 139(3), 2000, pp. 503-510
Authors:
Cleland, JGF
Massie, BM
Packer, M
Citation: Jgf. Cleland et al., Sudden death in heart failure: vascular or electrical?, EUR J HE FA, 1(1), 1999, pp. 41-45
Authors:
Cleland, JGF
Armstrong, P
Horowitz, JD
Massie, B
Packer, M
Poole-Wilson, PA
Ryden, L
Citation: Jgf. Cleland et al., Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study, EUR J HE FA, 1(1), 1999, pp. 73-79
Authors:
Packer, M
Citation: M. Packer, Implications of the ATLAS study for clinical practice, INT J CL PR, 1999, pp. 21-23
Authors:
Packer, M
Greco-Brooks, D
Citation: M. Packer et D. Greco-brooks, School as a site for the production of persons, J CONSTR PS, 12(2), 1999, pp. 133-151
Authors:
Adams, KF
Baughman, KL
Dec, WG
Elkayam, U
Forker, AD
Gheorghiade, M
Hermann, D
Konstam, MA
Liu, P
Massie, BM
Patterson, JH
Silver, MA
Stevenson, LW
Feldman, AM
Cohn, JN
Francis, GS
Greenberg, B
Konstam, MA
Leier, C
Lorell, BH
Packer, M
Pitt, B
Silver, MA
Sonnenblick, E
Strobeck, J
Walsh, R
Yusuf, S
Citation: Kf. Adams et al., HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches - Heart Failure Society of America, J CARD FAIL, 5(4), 1999, pp. 357-382
Authors:
Packer, M
Poole-Wilson, PA
Armstrong, PW
Cleland, JGF
Horowitz, JD
Massie, BM
Ryden, L
Thygesen, K
Uretsky, BF
Citation: M. Packer et al., Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, CIRCULATION, 100(23), 1999, pp. 2312-2318
Authors:
Rose, EA
Moskowitz, AJ
Packer, M
Sollano, JA
Williams, DL
Tierney, AR
Heitjan, DF
Meier, P
Ascheim, DD
Levitan, RG
Weinberg, AD
Stevenson, LW
Shapiro, PA
Lazar, RM
Watson, JT
Goldstein, DJ
Gelijns, AC
Citation: Ea. Rose et al., The REMATCH trial: Rationale, design, and end points, ANN THORAC, 67(3), 1999, pp. 723-730
Authors:
Packer, M
Miller, AB
Citation: M. Packer et Ab. Miller, Can physicians always explain the results of clinical trials? A case studyof amlodipine in heart failure, AM J CARD, 84(4A), 1999, pp. 1L-2L
Authors:
Packer, M
Cohn, JN
Citation: M. Packer et Jn. Cohn, Consensus recommendations for the management of chronic heart failure - Introduction, AM J CARD, 83(2A), 1999, pp. 1A-38A